Stem cell biology and regenerative medicine, Год журнала: 2024, Номер unknown, С. 279 - 336
Опубликована: Янв. 1, 2024
Язык: Английский
Stem cell biology and regenerative medicine, Год журнала: 2024, Номер unknown, С. 279 - 336
Опубликована: Янв. 1, 2024
Язык: Английский
Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12
Опубликована: Июль 18, 2024
Graphical Abstract Created using Biorender.com .
Язык: Английский
Процитировано
6Cancer Cell International, Год журнала: 2024, Номер 24(1)
Опубликована: Дек. 18, 2024
Cancer remains a significant global challenge, and despite the numerous strategies developed to advance cancer therapy, an effective cure for metastatic elusive. A major hurdle in treatment success is ability of cells, particularly stem cells (CSCs), resist therapy. These CSCs possess unique abilities, including self-renewal, differentiation, repair, which drive tumor progression chemotherapy resistance. The resilience linked certain signaling pathways. Tumors with pathway-dependent often develop genetic resistance, whereas those pathway-independent undergo epigenetic changes that affect gene regulation. can evade cytotoxic drugs, radiation, apoptosis by increasing drug efflux transporter activity activating survival mechanisms. Future research should prioritize identification new biomarkers molecules better understand use cutting-edge approaches, such as bioinformatics, genomics, proteomics, nanotechnology, offers potential solutions this challenge. Key include developing targeted therapies, employing nanocarriers precise delivery, focusing on CSC-targeted pathways Wnt, Notch, Hedgehog Additionally, investigating multitarget inhibitors, immunotherapy, nanodrug delivery systems critical overcoming resistance cells.
Язык: Английский
Процитировано
5Archives of Toxicology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 9, 2025
Язык: Английский
Процитировано
0British Journal of Cancer, Год журнала: 2025, Номер unknown
Опубликована: Март 12, 2025
Abstract Background The heterogeneity of tumors significantly impacts on colorectal cancer (CRC) progression. However, the influence this spatial architecture CRC remains largely unknown. Methods Spatial transcriptomic (ST) analysis AOM/DSS-induced (CRC), integrated with single-cell RNA sequencing, generated a comprehensive atlas CRC. Pseudotime trajectory, stemness evaluation, and cell-cell communication analyses explored how CD44 + tumor cells at leading edge remodel microenvironment (TME). In vitro experiments immunofluorescence staining clinical samples validated pleiotrophin (PTN) signaling in promoting cancer-associated fibroblasts (CAFs) phenotypic transition Results Our findings revealed distinctive layered ring-like structure within tissues, where exhibiting high were positioned tumor’s edge. Inflammatory CAFs (iCAFs)-like, myofibroblastic (myCAFs)-like pro-tumorigenic neutrophils primarily located edge, proximity to cells. then triggered into iCAF-like myCAF-like through PTN signaling. Conclusions results provide insights reshapes TME tumor, thereby
Язык: Английский
Процитировано
0Cancers, Год журнала: 2024, Номер 16(16), С. 2797 - 2797
Опубликована: Авг. 8, 2024
This review delves into the intricate roles of interleukin-8 (IL-8) and its receptors, CXCR1 CXCR2, in prostate cancer (PCa), particularly castration-resistant (CRPC) metastatic CRPC (mCRPC). emphasizes crucial role tumour microenvironment (TME) inflammatory cytokines promoting progression response to cell targeting agents. IL-8, acting through C-X-C chemokine receptor type 1 (CXCR1) 2 (CXCR2), modulates multiple signalling pathways, enhancing angiogenesis, proliferation, migration cells. highlights shift PCa research focus from solely cells non-cancer-cell components, including vascular endothelial cells, extracellular matrix, immune dynamic interactions within TME. The immunosuppressive nature TME significantly influences resistance emerging therapies. Current treatment modalities, androgen deprivation therapy chemotherapeutics, encounter persistent are complicated by cancer’s notably “immune-cold” nature, which limits system tumour. These challenges underscore critical need for novel approaches that both overcome enhance engagement therapeutic potential inhibiting IL-8 is explored, with studies showing enhanced sensitivity treatments, radiation inhibitors. Clinical trials, such as ACE trial, demonstrate efficacy combining CXCR2 inhibitors existing offering significant benefits, especially patients resistant PCa. also addresses chemokines, noting complexity precision avoid side effects optimize outcomes.
Язык: Английский
Процитировано
4Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 12
Опубликована: Янв. 3, 2025
Recent experimental findings indicate that cancer stem cells originate from transformed very small embryonic-like cells. This finding represents an essential advancement in uncovering the processes drive onset and progression of cancer. In continuously growing cell lines, for first time, our team's follow-up research on leukemia, lung cancer, healthy embryonic kidney revealed stages resembles precursor review explores origin leukemic stem-like establish We explore theoretical model acute myeloid leukemia initiation progresses through various stages, as well basing HL60 line, present its hierarchical stage development vitro, highlighting role these primitive stages. also discuss potential implications further into unique cellular advancing treatment prevention.
Язык: Английский
Процитировано
0Cancer Pathogenesis and Therapy, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0Stem Cell Reviews and Reports, Год журнала: 2025, Номер unknown
Опубликована: Март 17, 2025
Язык: Английский
Процитировано
0European Journal of Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 117598 - 117598
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0Current Oncology, Год журнала: 2025, Номер 32(4), С. 232 - 232
Опубликована: Апрель 16, 2025
Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% all head neck cancers. While surgical resection radiotherapy remain the standard locoregional control, systemic treatment is indicated recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, RET receptors. These facilitated development targeted therapies, including TRK inhibitors, HER2-directed agents, receptor modulators, well emerging combinations immunotherapy chemotherapy. Despite these advancements, challenges resistance mechanisms limited therapeutic efficacy persist. Overall response rates relatively low across most reflecting persistent unmet clinical need. This review discusses current landscape options explores promising trials future directions to enhance outcomes patients with SGCs.
Язык: Английский
Процитировано
0